A citation-based method for searching scientific literature

Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen, Lai-Shan Tam, Carlo Salvarani, Tae-Hwan Kim, Alan Solinger, Yakov Datsenko, Chandrasena Pamulapati, Sudha Visvanathan, David B Hall, Stella Aslanyan, Paul Scholl, Steven J Padula. Ann Rheum Dis 2018
Times Cited: 183







List of co-cited articles
1389 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
Atul Deodhar, Lianne S Gensler, Joachim Sieper, Michael Clark, Cesar Calderon, Yuhua Wang, Yiying Zhou, Jocelyn H Leu, Kim Campbell, Kristen Sweet,[...]. Arthritis Rheumatol 2019
158
58

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
Jonathan P Sherlock, Barbara Joyce-Shaikh, Scott P Turner, Cheng-Chi Chao, Manjiri Sathe, Jeff Grein, Daniel M Gorman, Edward P Bowman, Terrill K McClanahan, Jennifer H Yearley,[...]. Nat Med 2012
702
39

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
583
34

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression.
Richard James Cuthbert, Abdulla Watad, Evangelos M Fragkakis, Robert Dunsmuir, Peter Loughenbury, Almas Khan, Peter A Millner, Adam Davison, Helena Marzo-Ortega, Darren Newton,[...]. Ann Rheum Dis 2019
71
40

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
992
28


Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik. Ann Rheum Dis 2017
194
23

IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis.
Eric Gracey, Zoya Qaiyum, Ibrahim Almaghlouth, Daeria Lawson, Susan Karki, Naga Avvaru, Zhenbo Zhang, Yuchen Yao, Vidya Ranganathan, Yuriy Baglaenko,[...]. Ann Rheum Dis 2016
156
23

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling.
Melissa N van Tok, Songqing Na, Christopher R Lao, Marina Alvi, Desirée Pots, Marleen G H van de Sande, Joel D Taurog, Jonathon D Sedgwick, Dominique L Baeten, Leonie M van Duivenvoorde. Front Immunol 2018
47
44

Interleukin-23-Dependent γ/δ T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice.
Annika Reinhardt, Tetyana Yevsa, Tim Worbs, Stefan Lienenklaus, Inga Sandrock, Linda Oberdörfer, Thomas Korn, Siegfried Weiss, Reinhold Förster, Immo Prinz. Arthritis Rheumatol 2016
129
20

Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells.
Peggy Jacques, Stijn Lambrecht, Eveline Verheugen, Elin Pauwels, George Kollias, Maria Armaka, Marleen Verhoye, Annemie Van der Linden, Rik Achten, Rik J Lories,[...]. Ann Rheum Dis 2014
252
20

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados,[...]. Ann Rheum Dis 2017
821
20

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen,[...]. Lancet 2018
132
19

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.
Adrian Cortes, Johanna Hadler, Jenny P Pointon, Philip C Robinson, Tugce Karaderi, Paul Leo, Katie Cremin, Karena Pryce, Jessica Harris, Seunghun Lee,[...]. Nat Genet 2013
526
19

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.
Jacob S Lee, Cristina M Tato, Barbara Joyce-Shaikh, Muhammet F Gulen, Corinne Cayatte, Yi Chen, Wendy M Blumenschein, Michael Judo, Gulesi Ayanoglu, Terrill K McClanahan,[...]. Immunity 2015
420
18

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
525
18

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Désirée van der Heijde, Lianne S Gensler, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Alan Kivitz, Mary Katherine Farmer, Dominique Baeten, Nadine Goldammer, Jason Coarse,[...]. Ann Rheum Dis 2020
49
34

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Atul Deodhar, Désirée van der Heijde, Lianne S Gensler, Tae-Hwan Kim, Walter P Maksymowych, Mikkel Østergaard, Denis Poddubnyy, Helena Marzo-Ortega, Louis Bessette, Tetsuya Tomita,[...]. Lancet 2020
89
19

Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.
Ellen M Gravallese, Georg Schett. Nat Rev Rheumatol 2018
98
16

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.
Paul R Burton, David G Clayton, Lon R Cardon, Nick Craddock, Panos Deloukas, Audrey Duncanson, Dominic P Kwiatkowski, Mark I McCarthy, Willem H Ouwehand, Nilesh J Samani,[...]. Nat Genet 2007
16

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Stefan Siebert, Neal L Millar, Iain B McInnes. Ann Rheum Dis 2019
54
29

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
290
16

RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.
Koen Venken, Peggy Jacques, Céline Mortier, Mark E Labadia, Tine Decruy, Julie Coudenys, Kathleen Hoyt, Anita L Wayne, Robert Hughes, Michael Turner,[...]. Nat Commun 2019
127
16

Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice.
Helen Benham, Linda M Rehaume, Sumaira Z Hasnain, Jared Velasco, Athan C Baillet, Merja Ruutu, Kristine Kikly, Ran Wang, Hsu-Wen Tseng, Gethin P Thomas,[...]. Arthritis Rheumatol 2014
143
16

Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.
Richard J Cuthbert, Evangelos M Fragkakis, Robert Dunsmuir, Zhi Li, Mark Coles, Helena Marzo-Ortega, Peter V Giannoudis, Elena Jones, Yasser M El-Sherbiny, Dennis McGonagle. Arthritis Rheumatol 2017
93
17

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
313
15

Identification of myeloid cells in the human enthesis as the main source of local IL-23 production.
Charlie Bridgewood, Abdulla Watad, Tobias Russell, Timothy M Palmer, Helena Marzo-Ortega, Almas Khan, Peter A Millner, Robert Dunsmuir, Abhay Rao, Peter Loughenbury,[...]. Ann Rheum Dis 2019
46
32

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
15

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Désirée van der Heijde, In-Ho Song, Aileen L Pangan, Atul Deodhar, Filip van den Bosch, Walter P Maksymowych, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui,[...]. Lancet 2019
111
15

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Elizabeth G Araujo, Matthias Englbrecht, Sabrina Hoepken, Stephanie Finzel, Eleni Kampylafka, Arnd Kleyer, Sarah Bayat, Verena Schoenau, Axel Hueber, Juergen Rech,[...]. Semin Arthritis Rheum 2019
65
21

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
603
14

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.
Sarah L Gaffen, Renu Jain, Abhishek V Garg, Daniel J Cua. Nat Rev Immunol 2014
954
14

Enthesitis: from pathophysiology to treatment.
Georg Schett, Rik J Lories, Maria-Antonietta D'Agostino, Dirk Elewaut, Bruce Kirkham, Enrique R Soriano, Dennis McGonagle. Nat Rev Rheumatol 2017
194
14

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
M Rudwaleit, D van der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, J Braun, C T Chou, E Collantes-Estevez, M Dougados,[...]. Ann Rheum Dis 2009
14

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Denis Poddubnyy, Kay-Geert A Hermann, Johanna Callhoff, Joachim Listing, Joachim Sieper. Ann Rheum Dis 2014
190
14

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Atul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, Carlo Salvarani, Eric Lespessailles, Proton Rahman, Pentti Järvinen, Juan Sanchez-Burson, Karl Gaffney, Eun Bong Lee,[...]. Arthritis Rheumatol 2019
96
14

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Dominique Baeten, Xenofon Baraliakos, Jürgen Braun, Joachim Sieper, Paul Emery, Désirée van der Heijde, Iain McInnes, Jacob M van Laar, Robert Landewé, Paul Wordsworth,[...]. Lancet 2013
426
14

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
14

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Denis Poddubnyy, Paul Emery, Eumorphia M Delicha, Zsolt Talloczy, Brian Porter. Rheumatology (Oxford) 2019
74
17

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
530
13

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia. Lancet 2018
104
13


β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice.
Merja Ruutu, Gethin Thomas, Roland Steck, Mariapia A Degli-Esposti, Martin S Zinkernagel, Kylie Alexander, Jared Velasco, Geoffrey Strutton, Ai Tran, Helen Benham,[...]. Arthritis Rheum 2012
162
13

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.
Dennis G McGonagle, Iain B McInnes, Bruce W Kirkham, Jonathan Sherlock, Robert Moots. Ann Rheum Dis 2019
80
16

HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.
Monica L DeLay, Matthew J Turner, Erin I Klenk, Judith A Smith, Dawn P Sowders, Robert A Colbert. Arthritis Rheum 2009
259
13

IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass.
Iannis E Adamopoulos, Marlowe Tessmer, Cheng-Chi Chao, Sarvesh Adda, Dan Gorman, Mary Petro, Chuan-Chu Chou, Robert H Pierce, Wei Yao, Nancy E Lane,[...]. J Immunol 2011
123
13

Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis.
Mary-Ellen Costello, Francesco Ciccia, Dana Willner, Nicole Warrington, Philip C Robinson, Brooke Gardiner, Mhairi Marshall, Tony J Kenna, Giovanni Triolo, Matthew A Brown. Arthritis Rheumatol 2015
243
12

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.
Francesco Ciccia, Giuliana Guggino, Aroldo Rizzo, Laura Saieva, Sergio Peralta, AnnaRita Giardina, Alessandra Cannizzaro, Guido Sireci, Giacomo De Leo, Riccardo Alessandro,[...]. Ann Rheum Dis 2015
193
12

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler,[...]. Lancet 2017
267
12

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.